HC Wainwright Has Bearish Forecast for STOK FY2029 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities research analysts at HC Wainwright dropped their FY2029 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a research report issued on Wednesday, November 5th. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings per share of $0.35 for the year, down from their prior estimate of $0.46. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share.

A number of other research analysts also recently weighed in on the company. Wedbush raised their price target on Stoke Therapeutics from $22.00 to $32.00 and gave the company an “outperform” rating in a research note on Wednesday. JPMorgan Chase & Co. increased their price target on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a research note on Monday. Weiss Ratings restated a “sell (d+)” rating on shares of Stoke Therapeutics in a research note on Wednesday, October 8th. Canaccord Genuity Group upped their target price on shares of Stoke Therapeutics from $24.00 to $28.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Chardan Capital reiterated a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $31.00.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK opened at $22.82 on Thursday. The company’s 50-day moving average price is $26.35 and its two-hundred day moving average price is $17.03. Stoke Therapeutics has a one year low of $5.35 and a one year high of $38.69. The stock has a market capitalization of $1.25 billion, a PE ratio of 34.06 and a beta of 1.32.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.11). Stoke Therapeutics had a return on equity of 13.31% and a net margin of 19.73%.The business had revenue of $10.63 million for the quarter, compared to the consensus estimate of $6.06 million.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 45,996 shares of the firm’s stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $20.13, for a total transaction of $925,899.48. Following the completion of the transaction, the director owned 91,585 shares in the company, valued at approximately $1,843,606.05. This trade represents a 33.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Jonathan Allan sold 14,922 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $20.14, for a total value of $300,529.08. Following the sale, the general counsel owned 18,176 shares of the company’s stock, valued at approximately $366,064.64. The trade was a 45.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 186,607 shares of company stock valued at $4,224,210 in the last ninety days. 9.50% of the stock is currently owned by company insiders.

Institutional Trading of Stoke Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Siren L.L.C. grew its position in Stoke Therapeutics by 12.4% in the 1st quarter. Siren L.L.C. now owns 2,247,347 shares of the company’s stock worth $14,945,000 after purchasing an additional 247,347 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of Stoke Therapeutics in the 2nd quarter worth about $402,000. KLP Kapitalforvaltning AS grew its position in Stoke Therapeutics by 131.6% during the second quarter. KLP Kapitalforvaltning AS now owns 13,200 shares of the company’s stock valued at $150,000 after buying an additional 7,500 shares during the period. Invesco Ltd. increased its holdings in Stoke Therapeutics by 117.0% during the first quarter. Invesco Ltd. now owns 26,183 shares of the company’s stock worth $174,000 after buying an additional 14,118 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Stoke Therapeutics during the first quarter worth about $2,376,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.